Microba Life Sciences Limited
ASX: MAP
Strong growth outlook overshadowed by weak momentum and uncertain near-term execution risks.
(Source: TradingView) 3-Month Performance Profile of MAP on a DTF compared to S&P/ASX 200 (XJO).
Microba Life Sciences reported strong growth in FY25, with revenue reaching $15.67 million, driven by a 161% increase in core test volumes
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
